Article

Adenosine receptors as drug targets - what are the challenges?

Department of Neurology and Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
dressNature Reviews Drug Discovery (Impact Factor: 37.23). 03/2013; 12(4):265-286. DOI: 10.1038/nrd3955
Source: PubMed

ABSTRACT Adenosine signalling has long been a target for drug development, with adenosine itself or its derivatives being used clinically since the 1940s. In addition, methylxanthines such as caffeine have profound biological effects as antagonists at adenosine receptors. Moreover, drugs such as dipyridamole and methotrexate act by enhancing the activation of adenosine receptors. There is strong evidence that adenosine has a functional role in many diseases, and several pharmacological compounds specifically targeting individual adenosine receptors - either directly or indirectly - have now entered the clinic. However, only one adenosine receptor-specific agent - the adenosine A2A receptor agonist regadenoson (Lexiscan; Astellas Pharma) - has so far gained approval from the US Food and Drug Administration (FDA). Here, we focus on the biology of adenosine signalling to identify hurdles in the development of additional pharmacological compounds targeting adenosine receptors and discuss strategies to overcome these challenges.

0 Bookmarks
 · 
324 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Crystal structures of G protein-coupled receptors (GPCRs) have recently revealed the molecular basis of ligand binding and activation, which has provided exciting opportunities for structure-based drug design. The A2A adenosine receptor (A2AAR) is a promising therapeutic target for cardiovascular diseases, but progress in this area is limited by the lack of novel agonist scaffolds. We carried out docking screens of 6.7 million commercially available molecules against active-like conformations of the A2AAR to investigate if these structures could guide the discovery of agonists. Nine out of the 20 predicted agonists were confirmed to be A2AAR ligands, but none of these activated the ARs. The difficulties to discover AR agonists using structure-based methods originated from limited atomic-level understanding of the activation mechanism and a chemical bias towards antagonists in the screened library. In particular, the composition of the screened library was found to strongly reduce the likelihood of identifying AR agonists, which reflected the high ligand complexity required for receptor activation. Extension of this analysis to other pharmaceutically relevant GPCRs suggested that library screening may not be suitable for targets requiring a complex receptor-ligand interaction network. Our results provide specific directions for future development of novel A2AAR agonists and general strategies for structure-based drug discovery.
    Journal of Chemical Information and Modeling 01/2015; DOI:10.1021/ci500639g · 4.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: High throughput screening of combinatorial chemical libraries is a powerful approach for identifying targeted molecules. The display of combinatorial peptide libraries on the surface of bacteriophages offers a rapid, economical way to screen billions of peptides for specific binding properties and has impacted fields ranging from cancer to vaccine development. As a modification to this approach, we have previously created a system that enables site-specific insertion of selenocysteine (Sec) residues into peptides displayed pentavalently on M13 phage as pIII coat protein fusions. In this study, we show the utility of selectively derivatizing these Sec residues through the primary amine of small molecules that target a G protein-coupled receptor, the adenosine A1 receptor, leaving the other coat proteins including the major coat protein pVIII unmodified. We further demonstrate that modified Sec-phage with multivalent bound agonist bind to cells and elicit downstream signaling with orders of magnitude greater potency than unconjugated agonist. Our results provide proof of concept of a system that can create hybrid, small-molecule containing peptide libraries and opens up new possibilities for phage-drug therapies.
    Bioconjugate Chemistry 02/2015; DOI:10.1021/acs.bioconjchem.5b00011 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A novel one-pot synthesis of tri-substituted purines and the discovery of purine analogues with trypanocidal activity are reported. The reaction is initiated by a metal-free oxidative coupling of primary alkoxides and diaminopyrimidines with Schiff base formation and subsequent annulation in the presence of large N,N-dimethylamides (e.g. N,N-dimethylpropanamide or larger). This synthetic route is in competition with a reaction previously-reported by our group1, allowing the generation of a combinatorial library of tri-substituted purines by the simple modification of the amide and the alkoxide employed. Among the variety of structures generated, two purine analogues displayed trypanocidal activity against the protozoan parasite Trypanosoma brucei with IC50 < 5 μM, being each of those compounds obtained through each of the synthetic pathways.
    Scientific Reports 03/2015; 5(9139). DOI:10.1038/srep09139 · 5.08 Impact Factor

Full-text

Download
310 Downloads
Available from
May 15, 2014